• Publications
  • Influence
A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer
Purpose: To determine the safety, gene transfer, host immune response, and pharmacokinetics of a replication-deficient adenovirus encoding human, recombinant, wild-type p53 (SCH 58500) delivered intoExpand
  • 161
  • 7
A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a
BACKGROUND Nab-paclitaxel is a novel Cremophor®-free nanoparticle of albumin-stabilized paclitaxel, which has favorable efficacy and toxicity characteristics relative to other solvent-based taxanes,Expand
  • 77
  • 3
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
OBJECTIVES Preclinical data suggest an important role for the sarcoma proto-oncogene tyrosine kinase (SRC) in the oncogenesis of epithelial ovarian cancer (EOC) or primary peritoneal carcinoma (PPC).Expand
  • 38
  • 3
Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.
Purpose Guidelines are limited for genetic testing for prostate cancer (PCA). The goal of this conference was to develop an expert consensus-driven working framework for comprehensive geneticExpand
  • 71
  • 2
  • PDF
Failure of BRCA1 dysfunction to alter ovarian cancer survival.
PURPOSE Many factors modify ovarian cancer survival. There are conflicting reports regarding survival of individuals with hereditary BRCA1-related ovarian cancer. None have controlled for otherExpand
  • 41
  • 2
  • PDF
The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.
PURPOSE Cancer-specific p53 mutational spectra have been identified. Data from murine models and human BRCA1-related hereditary breast cancers suggest that both unique and specific BRCA1-associatedExpand
  • 33
  • 2
  • PDF
The glutathione S-transferase M1 genotype in ovarian cancer.
Glutathione S-transferase mu-1 (GSTM1) is a polymorphic member of the mu class gene family of the glutathione S-transferases. Individuals who are GSTM1 null have increased susceptibility to lung andExpand
  • 38
  • 2
  • PDF
A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.
OBJECTIVE This two-stage Phase II study assessed the activity of single agent alisertib in patients with recurrent/persistent uterine leiomyosarcoma (uLMS). METHODS Eligibility criteria includedExpand
  • 9
  • 2
Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy.
BACKGROUND Ovarian cancer diagnosed during pregnancy is uncommon. Paclitaxel-based chemotherapy during pregnancy has not been reported previously. CASE A woman with ascites and an adnexal massExpand
  • 135
  • 1
The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma
The prognostic significance and nature of p53 dysfunction in ovarian carcinoma is unclear. The relation between p53 overexpression, p53 mutations, and their effects on overall survival in primaryExpand
  • 131
  • 1